A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Sequential Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GCC-4401C in Healthy Males

Trial Profile

A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Sequential Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GCC-4401C in Healthy Males

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Dec 2014

At a glance

  • Drugs GC 2107 (Primary) ; Rivaroxaban
  • Indications Embolism; Stroke; Venous thromboembolism
  • Focus Adverse reactions
  • Sponsors Green Cross
  • Most Recent Events

    • 18 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 09 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top